# Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients

> **NCT02109562** · PHASE3 · COMPLETED · sponsor: **Indivior Inc.** · enrollment: 354 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** RBP-7000
- **DRUG:** Placebo
- **DRUG:** Risperidone

## Key facts

- **NCT ID:** NCT02109562
- **Lead sponsor:** Indivior Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 354 (ACTUAL)
- **Last updated:** 2018-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02109562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02109562, "Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02109562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*